NOV 18, 2019 8:37 PM PST

FDA Approves New Drug for Sickle Cell Disease

WRITTEN BY: Annie Lennon

Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting it out of reach of most, with other ways of managing the disease limited to preventative care. Now however, how these symptoms are managed may change with the FDA approval of the first ever targeted therapy for Sickle Cell Disease, Adakveo, developed by pharmaceutical company, Novartis. 

Normally, red blood cells are disk-like in shape. However, due to a genetic mutation for those with Sickle Cell Disease, their red blood cells resemble C-shaped crescents of “sickles”. Due to their shape, they often get stuck to the walls of blood vessels where they cause blockages. This may then result in vaso-occlusive crises in which blood flow to certain parts of the body is blocked (Lee: 2019). 

Leading to severe pain and potential organ damage due to deprivation of oxygen, until now, the only way to manage such crises has been to avoid certain triggers, such as high elevation, extreme cold, physical exhaustion and certain drugs such as acetazolamide. 

Now however, with Adakveo, also known as crizanlizumab-tmca, people with the disease may have another option. For those affected, a protein known as P-selectin found on the cellular lining inside blood vessel walls and platelets enables crescent-shaped red blood cells to stick to blood vessel walls, thus causing blockages. Adakveo works against ths by binding to and blocking P-selectin, thus preventing blockages and preventing vaso-occlusive crises (ibid.). 

The drug’s approval comes following results from a randomized clinical trial of 198 participants. There, researchers showed those who received Adakveo required an average of 1.63 hospital visits per year, whereas those on a placebo required an average of 2.98. The trial also found that those taking the drug had a longer time until experiencing their first vaso-occlusive crisis, and that 36% of those on the drug didn’t have a vaso-occlusive crisis at all throughout the study’s duration (FDA: 2019). 

According to Kenneth I. Attaga MD, director of the Center for Sickle Cell Disease at the University of Tennessee Health Science Center at Memphis, “We know this drug can decrease the frequency of sickle cell pain crisis in a significant and clinically meaningful way...The approval of crizanlizumab is an important advancement for people living with this very difficult condition (Kunzmann: 2019).”

 

Sources

 

Lee, Bruce: Forbes

FDA News

Kunzmann, Kevin: MDmag

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
FEB 10, 2021
Drug Discovery & Development
Ketamine Reduces Suicidal Thoughts in Patients with Depression
FEB 10, 2021
Ketamine Reduces Suicidal Thoughts in Patients with Depression
Ketamine has been known for some time for its ability to tackle depression. Now, however, researchers have found that or ...
FEB 20, 2021
Drug Discovery & Development
Deep Brain Stimulation Offsets Epileptic Seizures
FEB 20, 2021
Deep Brain Stimulation Offsets Epileptic Seizures
Researchers from the University of Freiburg in Germany have found that deep brain stimulation (DBS) in the brain’s ...
FEB 24, 2021
Drug Discovery & Development
Novel Neurofeedback Technique Improves Symptoms of Depression and Psychosis
FEB 24, 2021
Novel Neurofeedback Technique Improves Symptoms of Depression and Psychosis
Researchers from the University of Rochester have found that real-time functional magnetic resonance imaging (fMRI) neur ...
FEB 07, 2021
Drug Discovery & Development
Beta-Blockers Can Repair Broken Blood Vessels
FEB 07, 2021
Beta-Blockers Can Repair Broken Blood Vessels
Propranolol is a drug that can treat infantile haemangiomas but was found to also treat a blood vessel condition that le ...
APR 03, 2021
Drug Discovery & Development
Why Are Some Cancer Therapeutics Ineffective?
APR 03, 2021
Why Are Some Cancer Therapeutics Ineffective?
Why don’t some cancer therapeutics not work in humans when they were successful in mice? The answer to this questi ...
APR 17, 2021
Drug Discovery & Development
Nanofiber-Based Drug Treats Inflammation
APR 17, 2021
Nanofiber-Based Drug Treats Inflammation
Researchers at Duke University worked on creating a self-assembling nanomaterial-based drug that can help address damage ...
Loading Comments...